COVID-19 tedavisinde mezenkimal kök hücrelerin rolü

Yeni koronavirüs (SARS-CoV-2) salgını küresel bir sorun yarattı ve tıp dünyası hastalık için hızlı cevaplar aramaya başladı. Dünyanın dört bir yanındaki ilaç ve araştırma laboratuvarları, çeşitli farklı teknolojik yollar kullanarak yeni koro-navirüs için aşılar ve tedaviler bulmak için çabalamaktadır. Coronavirüs hasta-lığı (COVID-19) ile asemptomatik durumdan şiddetli semptomatik durumlara ve ölüme neden olabilmektedir. Sadece virüs enfeksiyonu ile ilişkili olmayan; sepsis, akut solunum sıkıntısı sendromu (ARDS) ve çoklu organ yetmezliğinin geliştiği gözlenir. Virüsün tedavisi ile birlikte neden olduğu sistemik inflamatuar yanıtın tedavisi de çok önemlidir. Vücudun enfesiyona verdiği hızlı yanıt iyi tanımlanmıştır ve sitokin fırtınası, endotel disfonksiyonu, inflamasyon ve patolojik pıhtılaşma arasında karmaşık bir etkileşim içerir. Etkili terapiler eksik olduğundan ve immünolojik tedaviler yetersiz olabileceğin-den, mezenkimal kök hücreler (MKH’ler), güçlü immünomodülatör yetenekleri nedeniyle, sitokin fırtınasını önlemek ve COVID-19'da morbidite ve mortaliteyi azaltmak için faydalı sonuçlara sahip olabilir. Bu makalenin amacı kesin tedavisi olmayan COVID-19 enfek-siyonunda MKH’in potansiyel etkilerini gözden geçirmektir.

The role of mesenchymal stem cells in COVID-19 treatment

The novel coronavirus (SARS-CoV-2) pandemic has created a sense of global panic and the medical community started to search for rapid answers. Pharmaceuticals and research labs across the world are racing to find vac-cines and treatments for the new coronavirus, using a variety of different technological ways. With Coronavirus disease (COVID-19), it is observed that asymptomatic symptoms turn out to be severe and fatal. By raising pyrexia, sepsis, acute respiratory distress syndrome (ARDS), and multiple organ failure are observed to develop which are not only associated with coronavirus. The treatment of the virus and the systemic inflammatory response it causes are also very important. The rapid response to infection has been well defined and comprises a complex interaction of cytokine storm, endothelial dysfunc-tion, inflammation, and pathologic coagulation. Since the effective therapies are missing and immunological treatments may be deficient, mesenchymal stem cells (MSCs), by reason of their potent immunomodulatory ability, can have useful results in order to prevent the cytokine storm and reduce morbid-ity and mortality for COVID-19. The aim of this article is to discuss the poten-tial effect of MSCs types in COVID-19 infection without definite treatment.

PDF

___

1. Khan S, Siddique R, Shereen MA, Ali A, Liu J, Bai Q, et al. emergence of a novel coronavirus, severe acute respiratory syndrome coronavirus 2: Biology and therapeutic options. J Clin Microbiol 2020; 58: e00187-20.
2. Yuen KS, Ye ZW, Fung SY, Chan CP, Jin DY. SARS-CoV-2 and COVID-19: The most important research questions. Cell Biosci 2020; 10: 40.
3. Wu D, Wu T, Liu Q, Yang Z. The SARS-CoV-2 outbreak: What we know. Int J Infect Dis 2020; 94: 44-8.
4. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506.
5. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med 2020: e200994.
6. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382: 1708-20.
7. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun 2020; 11: 222.
8. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet 2020; 395: 1033-4.
9. Khoury M, Cuenca J, Cruz FF, Figueroa FE, Rocco PRM, Weiss DJ. Current status of cell-based therapies for respiratory virus infections: applicability to COVID-19. Eur Respir J 2020; 55: 2000858.
10. Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020; 8: 420-2.
11. Bari E, Ferrarotti I, Torre ML, Corsico AG, Perteghella S. Mesenchymal stem/stromal cell secretome for lung regeneration: The long way through "pharmaceuticalization" for the best formulation. J Control Release 2019; 309: 11-24.
12. Bari E, Ferrarotti I, Saracino L, Perteghella S, Torre ML, Corsico AG. Mesenchymal stromal cell secretome for severe COVID-19 infections: premises for the therapeutic use. Cells 2020; 9: 924.
13. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Version 2. Proc Natl Acad Sci (USA) 2007; 104: 11002-7.
14. Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell 2012; 10: 709-16.
15. Liang B, Chen J, Li T, Wu H, Yang W, Li Y, et al. Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells. ChinaXiv 2020; 202002.00084.
16. Leng Z, Zhu R, Hou W, Feng Y, Yang Y, Han Q, et al. Transplantation of ACE2- mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia. Aging Dis 2020; 11: 216-28.
17. Cruz T, Rojas M. Preclinical Evidence for the Role of Stem/ Stromal Cells in Targeting ARDS. Burgess JK, Irene H (eds). Heijink. In: Stem cell-based therapy for lung disease. Springer Nature Switzerland AG 2019, 199-219.
18. Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 2015; 3: 24-32.
19. Darwish I, Mubareka S, Liles WC. Immunomodulatory therapy for severe influenza. Expert Rev Anti Infect Ther 2011; 9: 807-22.
20. Shen JF, Sugawara A, Yamashita J, Ogura H, Sato S. Dedifferentiated fat cells: an alternative source of adult multipotent cells from the adipose tissues. Int J Oral Sci 2011; 3: 117-24.
21. Sensebé L, Bourin P. Mesenchymal stem cells for therapeutic purposes. Transplantation 2009; 87: 49-53.
22. Zuk PA, Zhu M, Mizuno H, Huang J, Futrell JW, Katz AJ, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001; 7: 211-28.
23. Bernardo ME, Locatelli F, Fibbe WE. Mesenchymal stromal cells. Ann N Y Acad Sci 2009; 1176: 101-17.
24. Qayyum AA, Haack-Sørensen M, Mathiasen AB, Jørgensen E, Ekblond A, Kastrup J. Adipose-derived mesenchymal stromal cells for chronic myocardial ischemia (MyStromalCell Trial): study design. Regen Med 2012; 7: 421-8.
25. Yañez R, Lamana ML, García-Castro J, Colmenero I, Ramírez M, Bueren JA. Adipose tissue-derived mesenchymal stem cells have in vivo immunosuppressive properties applicable for the control of the graft-versus-host disease. Stem Cells 2006; 24: 2582-91.
26. Ivanova-Todorova E, Bochev I, Mourdjeva M, Dimitrov R, Bukarev D, Kyurkchiev S et al. Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett 2009; 126: 37-42.
27. Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res 2014; 15: 39.
28. Gentile P, Sterodimas A. Adipose-derived stromal stem cells (ASCs) as a new regenerative immediate therapy combating coronavirus (COVID-19)- induced pneumonia. Expert Opin Biol Ther 2020: 1-6.
29. Crivelli B, Chlapanidas T, Perteghella S, Lucarelli E, Pascucci L, Brini AT, et al. Mesenchymal stem/stromal cell extracellular vesicles: From active principle to next generation drug delivery system. J Control Release 2017; 262: 104-17.
30. Kyurkchiev D, Bochev I, Ivanova-Todorova E, Mourdjeva M, Oreshkova T, Belemezova K, et al. Secretion of immunoregulatory cytokines by mesenchymal stem cells. World J Stem Cells 2014; 6: 552-70.
31. Zhu YG, Feng XM, Abbott J, Fang XH, Hao Q, Monsel A, et al. Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin-induced acute lung injury in mice. Stem Cells 2014; 32: 116-25.
32. Zhu X, Badawi M, Pomeroy S, Sutaria DS, Xie Z, Baek A, et al. Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. J Extracell Vesicles 2017; 6: 1324730.
33. Arutyunyan I, Elchaninov A, Makarov A, Fatkhudinov T. Umbilical cord as prospective source for mesenchymal stem cell-based therapy. Stem Cells Int 2016; 2016: 6901286.
34. Weiss ML, Troyer DL. Stem cells in the umbilical cord. Stem Cell Rev 2006; 2: 155-62.
35. Atluri S, Manchikanti L, Hirsch JA. Expanded umbilical cord mesenchymal stem cells (UC-MSCs) as a therapeutic strategy in managing critically Ill COVID-19 patients: the case for compassionate use. Pain Physician 2020; 23: E71–E83.
36. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 2020; 191: 145-7.
37. Jung JW, Kwon M, Choi JC, Shin JW, Park IW, Choi BW, et al. Familial occurrence of pulmonary embolism after intravenous, adipose tissue-derived stem cell therapy. Yonsei Med J 2013; 54: 1293-6.
38. Tatsumi K, Ohashi K, Matsubara Y, Kohori A, Ohno T, Kakidachi H, et al. Tissue factor triggers procoagulation in transplanted mesenchymal stem cells leading to thromboembolism. Biochem Biophys Res Commun 2013; 431: 203-9.
39. Ji F, Li L, Li Z, Jin Y, Liu W. Mesenchymal stem cells as a potential treatment for critically ill patients with coronavirus disease 2019. Stem Cells Transl Med 2020: 10.1002/ sctm.20-0083.